Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ophthotech adds to aptamer pipeline in deal with Archemix

Executive Summary

Only a few weeks after buying OSI's preclinical aptamer program, Ophthotech is adding more of these single-stranded oligonucleotides to its pipeline through an exclusive worldwide license to two of Archemix's C5-blocking therapeutics for all ophthalmic indications. NOTE: One of those candidates is Zimura (avacincaptad pegol; ARC1905).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies